Select a medication above to begin.
Stivarga
regorafenib
Black Box Warnings .
Hepatotoxicity
severe and sometimes fatal hepatotoxicity observed in clinical trials; monitor LFTs at baseline, then at least q2wk x2mo, then qmo; interrupt tx and reduce dose or D/C tx if elev. LFTs or hepatocellular necrosis occurs
Adult Dosing .
Dosage forms: TAB: 40 mg
Special Note
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing incl. toxicity-related dose adjustments; D/C >2wk before elective surgery; restart >2wk after major surgery when wound fully healed
colorectal CA, refractory metastatic
- [160 mg PO qd on days 1-21 of 28-day cycle]
- Info: give w/ low-fat food
gastrointestinal stromal tumor, previously treated
- [160 mg PO qd on days 1-21 of 28-day cycle]
- Info: for pts w/ locally advanced, unresectable or metastatic dz who have received imatinib and sunitinib; give w/ low-fat food
hepatocellular CA, previously treated
- [160 mg PO qd on days 1-21 of 28-day cycle]
- Info: for pts w/ dz progression following sorafenib; give w/ low-fat food
renal dosing
- [see below]
- CrCl >15: no adjustment; CrCl <15: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- bilirubin 1.1-3x ULN or AST >ULN: no adjustment; bilirubin >3x ULN: not defined
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.